FDA Schedules Advisory Committee for Capricor's Deramiocel in Duchenne Muscular Dystrophy

San Diego-based Capricor Therapeutics (Nasdaq: CAPR) announced that the US FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will meet on July 29, 2026 to review the Biologics License Application (BLA) for deramiocel (CAP-1002), an allogeneic cell therapy for Duchenne muscular dystrophy (DMD). The AdCom meeting precedes a PDUFA target action date of August 22, 2026, placing a potential deramiocel FDA approval decision approximately eight weeks away.

The US FDA has scheduled the CTGTAC meeting as part of its ongoing BLA review for deramiocel in DMD. The AdCom convening is a procedural step in which the committee will assess the benefit-risk profile of the therapy and issue a non-binding recommendation. The BLA review is classified as a Class 2 resubmission — the US FDA having lifted a prior Complete Response Letter and resumed review in March 2026. The application is supported by positive Phase III HOPE-3 data demonstrating statistically significant improvement in upper limb function and cardiac measures.

Deramiocel consists of allogeneic cardiosphere-derived cells (CDCs) that secrete extracellular vesicles (exosomes), which reprogramme macrophages from a pro-inflammatory to a pro-healing phenotype, exerting immunomodulatory and anti-fibrotic effects on both cardiac and skeletal muscle.

DMD is a rare progressive neuromuscular disorder with no curative therapy. Deramiocel's dual skeletal and cardiac muscle benefit profile is positioned as potentially first-in-class; existing approved therapies in DMD — including exon-skipping agents — address the underlying genetic defect but do not specifically target the cardiac deterioration that is the leading cause of death in the disease.

The competitive landscape is intensifying. Waltham, Massachusetts-based Dyne Therapeutics (Nasdaq: DYN) filed a BLA for zeleciment rostudirsen (z-rostudirsen) targeting exon 51-amenable DMD, while Rockville, Maryland-based REGENXBIO (Nasdaq: RGNX) reported positive Phase III data for its gene therapy RGX-202. Neither directly replicates deramiocel's mechanism or cardiac endpoint focus.

Capricor also holds Orphan Drug Designation from both the US FDA and the European Medicines Agency, conferring seven-year US and ten-year EU market exclusivity post-approval. In addition, the filing holds Rare Pediatric Disease Designation, which may qualify the company for a transferable Priority Review Voucher upon approval — a potentially material financial asset independent of commercial revenues. While the committee's recommendation is non-binding, advisory committee votes are closely watched because they can influence expectations ahead of the FDA's final decision. The advisory committee will meet on July 29 ahead of the FDA's August 22 PDUFA target date, when the agency is expected to decide whether to approve deramiocel.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article